Latest Trials
Latest News
FAQ
Pharmaceutical Companies
Pharma Details
GENENTECH, INC.
🇺🇸
United States
Country
🇺🇸
United States
Ownership
Subsidiary
Established
1976-01-01
Employees
11.1K
Market Cap
-
Website
http://www.gene.com
Clinical Trials
Related News
A Study of Bevacizumab Plus Carboplatin and Paclitaxel in Subjects With Advanced, Previously Untreated, Squamous Non-Small Cell Lung Cancer (BRIDGE)
Phase 2
Completed
Conditions
Non-small Cell Lung Cancer
Interventions
Drug: Bevacizumab
Drug: Carboplatin
Drug: Paclitaxel
Subscribe
First Posted Date
2006-04-26
Last Posted Date
2010-05-11
Lead Sponsor
Genentech, Inc.
Target Recruit Count
47
Registration Number
NCT00318136
Subscribe
A Study of Omalizumab (Xolair) in Subjects With Moderate to Severe Persistent Asthma (EXTRA)
Phase 3
Completed
Conditions
Asthma
Interventions
Drug: omalizumab (Xolair)
Drug: placebo
Drug: corticosteroids
Drug: long-acting beta-agonists
Subscribe
First Posted Date
2006-04-14
Last Posted Date
2012-02-09
Lead Sponsor
Genentech, Inc.
Target Recruit Count
850
Registration Number
NCT00314574
Subscribe
A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)
Phase 2
Completed
Conditions
Non-Small Cell Lung Cancer
Brain Neoplasms
Interventions
Drug: bevacizumab
Drug: First-Line Chemotherapy Agents
Drug: Second-Line Chemotherapy Agents
Subscribe
First Posted Date
2006-04-11
Last Posted Date
2023-01-06
Lead Sponsor
Genentech, Inc.
Target Recruit Count
115
Registration Number
NCT00312728
Subscribe
A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Plaque Psoriasis Involving the Hands and/or Feet
Phase 4
Completed
Conditions
Psoriasis
Subscribe
First Posted Date
2006-04-07
Last Posted Date
2017-02-15
Lead Sponsor
Genentech, Inc.
Target Recruit Count
75
Registration Number
NCT00312026
Subscribe
A Study to Determine the Variability of a 6-Minute Walk Test in Cystic Fibrosis Subjects With Advanced Lung Disease
Completed
Conditions
Cystic Fibrosis
Subscribe
First Posted Date
2006-04-06
Last Posted Date
2017-05-16
Lead Sponsor
Genentech, Inc.
Target Recruit Count
25
Registration Number
NCT00311506
Subscribe
Cathflo Activase Pediatric Study
Phase 4
Completed
Conditions
Dysfunctional Central Venous Access Devices (CVADS)
Subscribe
First Posted Date
2006-03-28
Last Posted Date
2014-04-09
Lead Sponsor
Genentech, Inc.
Target Recruit Count
300
Registration Number
NCT00307580
Subscribe
A Study to Evaluate Rituximab in Combination With Methotrexate in Methotrexate-Naive Patients With Active Rheumatoid Arthritis
Phase 3
Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: folate
Drug: methotrexate
Drug: methylprednisolone
Drug: placebo
Drug: rituximab
Subscribe
First Posted Date
2006-03-06
Last Posted Date
2017-07-28
Lead Sponsor
Genentech, Inc.
Target Recruit Count
755
Registration Number
NCT00299104
Subscribe
A Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Active Rheumatoid Arthritis
Phase 3
Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: Folate
Drug: Methotrexate
Drug: Methylprednisolone
Drug: Placebo
Drug: Rituximab
Subscribe
First Posted Date
2006-03-06
Last Posted Date
2017-04-17
Lead Sponsor
Genentech, Inc.
Target Recruit Count
511
Registration Number
NCT00299130
Subscribe
Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Phase 3
Completed
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Drug: Placebo
Drug: Pirfenidone
Subscribe
First Posted Date
2006-02-07
Last Posted Date
2017-05-22
Lead Sponsor
Genentech, Inc.
Target Recruit Count
435
Registration Number
NCT00287716
Locations
🇺🇸
InterMune, Inc., Brisbane, California, United States
Subscribe
Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Phase 3
Completed
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Drug: Placebo
Drug: Pirfenidone
Subscribe
First Posted Date
2006-02-07
Last Posted Date
2017-04-17
Lead Sponsor
Genentech, Inc.
Target Recruit Count
344
Registration Number
NCT00287729
Locations
🇺🇸
InterMune, Inc., Brisbane, California, United States
Subscribe
Prev
1
40
41
42
43
44
49
Next
© Copyright 2024. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy